PDF Cover

Vutrisiran Market

The market for Vutrisiran was estimated at $833 million in 2024; it is anticipated to increase to $2.28 billion by 2030, with projections indicating growth to around $5.29 billion by 2035.

Report ID:DS1802062
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Vutrisiran
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Vutrisiran Market Outlook

Revenue, 2024

$833M

Forecast, 2034

$4.47B

CAGR, 2025 - 2034

18.3%

The Vutrisiran industry revenue is expected to be around $985.2 million in 2025 and expected to showcase growth with 18.3% CAGR between 2025 and 2034. This strong projected expansion underscores the growing clinical and commercial importance of vutrisiran within the evolving RNA interference therapeutics landscape. Increasing diagnosis rates of hereditary transthyretin-mediated amyloidosis and broader genetic screening initiatives are strengthening patient identification, thereby expanding the eligible treatment pool. At the same time, physician confidence in RNAi-based therapies continues to rise as long-term efficacy and safety data mature. Favorable reimbursement pathways in key developed markets, coupled with ongoing geographic expansion strategies, are reinforcing revenue visibility. Strategic lifecycle management efforts, including label expansion studies and real-world evidence generation, further sustain competitive positioning. As healthcare systems prioritize targeted therapies that address disease progression at the molecular level, vutrisiran maintains strong relevance within specialized rare disease treatment frameworks.

Vutrisiran, marketed under the brand name Amvuttra, is an RNA interference therapeutic designed to reduce transthyretin production in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Administered subcutaneously on a quarterly basis, it offers dosing convenience that supports patient adherence and long-term management. Its mechanism targets the underlying cause of disease rather than only alleviating symptoms, which enhances its clinical value proposition. Major applications center on rare neurological and cardiometabolic manifestations associated with transthyretin amyloidosis, with ongoing studies exploring broader indications. Recent demand trends are driven by expanding treatment guidelines, increasing specialist awareness, and improved access programs. As precision medicine gains further traction, Amvuttra continues to strengthen its role within the orphan drug and advanced biologics market segments.

Vutrisiran market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Vutrisiran Market Outlook

Market Key Insights

  • The Vutrisiran market is projected to grow from $832.8 million in 2024 to $4.47 billion in 2034. This represents a CAGR of 18.3%, reflecting rising demand across Hereditary Transthyretin-Mediated Amyloidosis and Polyneuropathy Management.

  • Alnylam Pharmaceuticals is the sole producer in this market, holding full control over supply and pricing.

  • U.S. and Germany are the top markets within the Vutrisiran market and are expected to observe the growth CAGR of 17.6% to 25.6% between 2024 and 2030.

  • Emerging markets including Brazil, Indonesia and South Africa are expected to observe highest growth with CAGR ranging between 13.7% to 19.0%.

  • Slow adoption of Transition from Symptom Management to Disease-Modifying RNAi Therapies in Amyloidosis Treatment transition within key players in Vutrisiran market is creating a revenue window for adjacent and alternate markets like Patisiran and Inotersen to improve its use-case penetration in ATTR Amyloidosis and Familial Amyloid Polyneuropathy applications and expected to capture $191 million revenue from existing Vutrisiran market.

  • The Vutrisiran market is set to add $3.6 billion between 2024 and 2034, with manufacturer targeting Patients & Pharmaceuticals Application projected to gain a larger market share.

  • With

    emerging therapies in transthyretin-mediated amyloidosis, and

    Expanding RNA interference Technology, Vutrisiran market to expand 437% between 2024 and 2034.

vutrisiran market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Vutrisiran - Country Share Analysis

Opportunities in the Vutrisiran

Partnerships between pharmaceutical companies, biotechnology startups, and academic research institutions represent another important opportunity for vutrisiran market growth. These collaborations help accelerate research in RNA interference therapeutics, expand clinical trials, and improve delivery technologies for gene-silencing drugs. Increasing funding from rare disease foundations and government programs is also encouraging multi-institutional research on transthyretin amyloidosis and related genetic disorders. Such collaborations often lead to improved treatment protocols and expanded indications. The RNAi-based therapy segment is expected to benefit most, particularly in biotechnology hubs in the United States and Europe where research infrastructure, venture funding, and orphan-drug development programs are well established.

Growth Opportunities in North America and Europe

North America represents the most advanced and commercially significant region for the vutrisiran market, driven by strong rare disease research infrastructure and early adoption of RNA interference therapeutics. The United States in particular benefits from high awareness of hereditary transthyretin amyloidosis and increasing screening through specialized neurology and cardiology centers. Regulatory approvals and supportive orphan-drug policies have accelerated market entry and reimbursement pathways, encouraging broader use of transthyretin amyloidosis therapies. Key opportunities in the region include expanding treatment for transthyretin amyloid cardiomyopathy and improving genetic testing programs that enable earlier diagnosis. Competition is intensifying as pharmaceutical companies introduce alternative ATTR treatments, prompting companies to emphasize clinical differentiation, patient support programs, and payer negotiations. Additionally, the presence of strong biotechnology ecosystems and specialty drug distribution networks supports commercialization. Overall, growing diagnosis rates, favorable reimbursement structures, and expanding cardiomyopathy treatment applications are expected to sustain strong regional growth in the North American vutrisiran market.
Europe is emerging as a significant growth region for the vutrisiran market, supported by expanding rare disease treatment frameworks and increasing focus on precision medicine. Countries such as Germany, the United Kingdom, France, and Italy are strengthening national programs for genetic disorder diagnosis, improving identification of hereditary transthyretin amyloidosis patients. European healthcare systems are gradually integrating advanced RNA interference therapies into treatment pathways for transthyretin amyloidosis, particularly following broader regulatory approvals and clinical guideline updates. One of the major opportunities in Europe lies in expanding access to therapies for transthyretin amyloid cardiomyopathy through specialized cardiac centers and cross-border rare disease networks. However, competition is increasing as multiple ATTR treatment options enter the market, leading to price negotiations with national healthcare payers. Cost-effectiveness evaluations by reimbursement agencies also influence adoption speed. Despite these challenges, rising awareness, growing diagnostic capabilities, and expanding rare disease funding are expected to support steady growth of vutrisiran therapies across Europe

Market Dynamics and Supply Chain

01

Driver: Rising prevalence of hereditary transthyretin amyloidosis and improved genetic diagnostics expanding patient identification

The increasing global prevalence of hereditary transthyretin-mediated amyloidosis (hATTR) is also a key driver supporting the demand for vutrisiran therapies. hATTR is also a rare but progressive genetic disorder caused by the accumulation of misfolded transthyretin proteins in nerves and organs, leading to neuropathy and cardiomyopathy. As awareness among clinicians grows, healthcare systems are also diagnosing more cases that were also previously misclassified as other neurological or cardiac disorders. Alongside this trend, also advances in genetic testing, biomarker-based diagnostics, and cardiac imaging technologies are also enabling earlier and more accurate identification of patients with transthyretin mutations. Early detection expands the treatable patient population and allows disease-modifying therapies like vutrisiran to be introduced before irreversible organ damage occurs. This convergence of improved diagnostics and expanding disease recognition is also reshaping treatment pathways and significantly increasing the eligible patient pool for RNA interference-based therapeutics targeting hATTR.
Technological progress in RNA interference therapeutics is also another major driver of the vutrisiran market. RNAi technology allows drugs to silence specific genes responsible for disease-causing proteins, providing a highly targeted therapeutic mechanism. Vutrisiran uses this approach to suppress the production of transthyretin protein in the liver, addressing the root cause of amyloidosis rather than only managing symptoms. Continuous improvements in RNAi delivery systems, molecular stability, and safety profiles have also enhanced drug precision and reduced adverse effects, making these therapies more viable for long-term management of genetic disorders. In addition, growing research investments and clinical trials in gene-silencing technologies are also accelerating innovation and regulatory approvals in the rare disease segment. These technological advancements are also positioning RNAi drugs as a transformative class of treatments, significantly boosting adoption of vutrisiran and similar next-generation therapies.
02

Restraint: Exceptionally high therapy pricing and reimbursement restrictions limiting patient access across healthcare systems

One of the most significant restraints affecting the adoption of vutrisiran is its exceptionally high treatment cost combined with complex reimbursement frameworks. The therapy is priced at roughly $477,000 annually, reflecting the high development costs and specialized manufacturing associated with RNA interference drugs. Healthcare payers and national health systems often conduct strict cost-effectiveness assessments before approving coverage for such expensive orphan drugs. As a result, patients frequently face prior-authorization requirements, regional reimbursement disparities, or delayed coverage decisions. For example, public healthcare programs may negotiate price reductions or restrict use to severe cases, which directly slows prescription volumes. These pricing pressures limit widespread adoption despite clinical benefits, reducing overall revenue potential and creating uneven market penetration across regions with different healthcare budgets and reimbursement policies.
03

Opportunity: Expansion of vutrisiran therapy into transthyretin amyloid cardiomyopathy treatment across North America and Europe and Increasing adoption of advanced genetic screening programs in Asia-Pacific enabling earlier diagnosis of hATTR patients

A major growth opportunity for vutrisiran lies in expanding its use for transthyretin amyloid cardiomyopathy (ATTR-CM), a rapidly recognized cardiac condition linked to transthyretin protein misfolding. Healthcare systems in North America and Europe are increasingly identifying ATTR-CM through improved cardiac imaging, genetic screening, and specialist referral networks. As clinical evidence supporting RNA interference therapies grows, regulatory approvals for broader cardiac indications could significantly expand the addressable patient population beyond neuropathy-focused treatment. The cardiology segment is expected to experience the fastest growth, particularly in advanced healthcare markets such as the United States, Germany, and the United Kingdom where rare disease diagnostics and specialty drug adoption are accelerating.
Growing implementation of genetic screening and precision medicine initiatives across the Asia-Pacific region presents a significant opportunity for vutrisiran adoption. Countries such as Japan, South Korea, and Singapore are expanding national programs focused on rare disease detection and genomic diagnostics. These initiatives allow earlier identification of hereditary transthyretin amyloidosis patients who may benefit from RNA interference therapies. As awareness of genetic disorders rises among clinicians and healthcare policymakers, demand for targeted disease-modifying treatments is expected to grow. The hereditary transthyretin amyloidosis treatment segment in Asia-Pacific is projected to experience notable expansion due to improving diagnostic infrastructure and supportive rare-disease healthcare policies.
04

Challenge: Limited patient population and persistent underdiagnosis of hereditary transthyretin amyloidosis

Another major restraint is the inherently small and often underdiagnosed patient population eligible for vutrisiran therapy. Hereditary transthyretin amyloidosis is a rare disorder with geographically dispersed cases, which inherently restricts the total addressable market for the drug. Additionally, the disease frequently presents with non-specific symptoms such as neuropathy or cardiomyopathy, causing patients to be misdiagnosed with more common conditions for years. This prolonged diagnostic journey delays treatment initiation and reduces the number of patients who ultimately receive disease-modifying therapies like vutrisiran. For instance, delayed recognition by primary care physicians can postpone specialist referral and genetic testing. Such diagnostic barriers constrain demand growth, limiting annual prescription volumes and slowing overall market expansion despite

Supply Chain Landscape

1

RNAi Raw Materials

Thermo Fisher ScientificMerck KGaAAgilent Technologies
2

Drug Manufacturing

Alnylam Pharmaceuticals
3

Distribution & Specialty Pharma

McKesson CorporationAmerisourceBergenCardinal Health
4

Clinical End Users

HospitalsSpecialty Neurology ClinicsCardiology Centers
Vutrisiran - Supply Chain

Use Cases of Vutrisiran in Hereditary Transthyretin-Mediated Amyloidosis & Polyneuropathy Management

Hereditary Transthyretin-Mediated Amyloidosis : Vutrisiran is primarily used in the treatment of hereditary transthyretin-mediated amyloidosis, a rare genetic disorder characterized by abnormal protein deposits that damage organs and tissues. In this application, vutrisiran’s RNA interference mechanism targets the production of transthyretin proteins in hepatocytes, reducing circulating mutant and wild-type proteins responsible for amyloid accumulation. Clinicians administer the therapy in outpatient settings, improving patient quality of life through disease-modifying effects rather than symptom suppression alone. The key advantage is its ability to address the underlying pathology with infrequent subcutaneous dosing, supporting adherence and long-term management in affected individuals.
Polyneuropathy Management : In polyneuropathy management, vutrisiran plays a critical therapeutic role for patients experiencing progressive nerve damage associated with transthyretin amyloidosis. Healthcare professionals use the drug to slow or stabilize neuropathic progression, thereby preserving motor and sensory function. This application benefits from early initiation guided by genetic screening and neurologic assessment, enabling personalized treatment pathways. The clinical benefit is evidenced by improved neuropathy scores and reduced disability progression compared to historical controls. By targeting the root cause of neural deterioration, vutrisiran supports multidisciplinary care strategies involving neurologists, cardiologists, and allied health specialists focused on maintaining functional independence.

Recent Developments

Recent developments in the vutrisiran market reflect strong momentum in RNA interference therapeutics for transthyretin amyloidosis. A key milestone was the U.S. FDA approval expanding vutrisiran (marketed as AMVUTTRA) for transthyretin amyloid cardiomyopathy, enabling treatment of both cardiomyopathy and polyneuropathy manifestations of ATTR disease. This expansion significantly broadens the addressable patient population and strengthens commercial potential in the rare disease therapeutics segment. A notable trend is intensifying competition among ATTR treatments, prompting pharmaceutical companies to prioritize gene-silencing drugs, strategic pricing models, and global regulatory expansion to capture growth in the evolving amyloidosis treatment landscape.

June 2025 : Alnylam Pharmaceuticals secured European Commission approval for AMVUTTRA for transthyretin amyloidosis with cardiomyopathy, enabling expanded commercialization across the European Union and strengthening its market presence in the ATTR-CM therapeutic segment.
March 2025 : Alnylam Pharmaceuticals obtained U.S. FDA approval for vutrisiran for the treatment of transthyretin amyloid cardiomyopathy, significantly expanding the drug’s indication beyond polyneuropathy and opening access to a multi-billion-dollar rare cardiovascular disease market.

Impact of Industry Transitions on the Vutrisiran Market

As a core segment of the Pharmaceutical industry, the Vutrisiran market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Symptom Management to Disease-Modifying RNAi Therapies in Amyloidosis Treatment and Transition toward Integrated Rare Disease Diagnosis and Specialty Care Networks have redefined priorities across the Pharmaceutical sector, influencing how the Vutrisiran market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Symptom Management to Disease-Modifying RNAi Therapies in Amyloidosis Treatment

The treatment landscape for hereditary transthyretin amyloidosis is transitioning from traditional symptom management toward disease-modifying RNA interference therapies such as vutrisiran. Earlier treatment approaches mainly focused on pain control, cardiac symptom relief, and organ support rather than addressing the underlying protein production causing the disease. With the introduction of RNAi therapeutics that suppress transthyretin production in the liver, pharmaceutical strategies are shifting toward targeted genetic treatments. This transition is influencing the broader rare-disease drug development ecosystem, encouraging biotechnology firms to invest in gene-silencing platforms. For example, pharmaceutical companies are expanding RNAi pipelines for liver-based genetic disorders, while specialty healthcare providers are developing dedicated amyloidosis treatment centers, increasing demand for precision medicines and specialized diagnostic services.
02

Transition toward Integrated Rare Disease Diagnosis and Specialty Care Networks

Another significant transition shaping the vutrisiran market is the movement toward integrated rare disease diagnosis and coordinated specialty care networks. Historically, patients with transthyretin amyloidosis often experienced long diagnostic delays due to fragmented healthcare pathways and limited physician awareness. Healthcare systems are now implementing structured referral networks, advanced genetic testing programs, and multidisciplinary amyloidosis clinics to streamline diagnosis and treatment. This shift is impacting several associated industries, including genetic testing laboratories, specialty pharmacy services, and rare disease diagnostics providers. For instance, hospitals and research institutions are collaborating with biotechnology companies to establish specialized amyloidosis programs, improving early patient identification and therapy adoption. As a result, demand is rising for targeted therapies like vutrisiran within coordinated rare-disease treatment ecosystems.